X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (746) 746
Book Review (112) 112
Publication (32) 32
Book Chapter (8) 8
Conference Proceeding (6) 6
Dissertation (3) 3
Government Document (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (501) 501
humans (334) 334
dpp-iv (323) 323
animals (243) 243
glucagon-like peptide-1 (212) 212
type 2 diabetes (197) 197
diabetes mellitus, type 2 - drug therapy (170) 170
dipeptidyl peptidase 4 - metabolism (169) 169
diabetes (167) 167
male (162) 162
dpp-iv inhibitor (149) 149
chemistry, medicinal (135) 135
endocrinology & metabolism (133) 133
rats (128) 128
pharmacology & pharmacy (117) 117
biochemistry & molecular biology (116) 116
glp-1 (116) 116
female (108) 108
dipeptidyl-peptidase iv inhibitors - pharmacology (105) 105
dpp-iv inhibitors (105) 105
hypoglycemic agents - therapeutic use (99) 99
sitagliptin (88) 88
mice (86) 86
glucose (80) 80
dipeptidyl-peptidase iv inhibitors - therapeutic use (79) 79
middle aged (79) 79
analysis (78) 78
peptides (77) 77
dipeptidyl peptidase 4 - chemistry (74) 74
chemistry, organic (73) 73
dipeptidyl-peptidase iv inhibitors - chemistry (69) 69
structure-activity relationship (68) 68
dipeptidyl peptidase iv (65) 65
glycemic control (65) 65
blood glucose - metabolism (63) 63
dipeptidyl-peptidase-iv (63) 63
aged (61) 61
diabetes mellitus (60) 60
hypoglycemic agents - pharmacology (60) 60
insulin (60) 60
inhibitor (58) 58
potent (58) 58
food science & technology (57) 57
sitagliptin phosphate (57) 57
inhibitors (55) 55
diabetes mellitus, type 2 - blood (53) 53
enzymes (53) 53
hypoglycemic agents (53) 53
proteins (53) 53
vildagliptin (53) 53
dpp iv (52) 52
dipeptidyl peptidase-iv (51) 51
type-2 diabetes-mellitus (49) 49
adult (48) 48
cd26 (47) 47
discovery (47) 47
dextrose (46) 46
double-blind (45) 45
dpp‐iv (45) 45
drug design (45) 45
treatment outcome (45) 45
double-blind method (44) 44
inhibition (44) 44
diabetes therapy (43) 43
incretins (43) 43
dipeptidyl-peptidase iv inhibitors (42) 42
dipeptidyl-peptidase iv inhibitors - administration & dosage (42) 42
metformin (42) 42
adamantane - analogs & derivatives (41) 41
beta-cell function (41) 41
blood glucose - drug effects (41) 41
protease inhibitors - pharmacology (41) 41
dose-response relationship, drug (40) 40
identification (40) 40
bioactive peptides (39) 39
care and treatment (39) 39
expression (39) 39
improved glucose-tolerance (39) 39
mellitus (38) 38
diabetes mellitus, type 2 - metabolism (37) 37
glucose tolerance test (37) 37
hydrolysis (37) 37
molecular structure (37) 37
glucagon (36) 36
hypoglycemic agents - chemistry (36) 36
incretin (36) 36
proteases (36) 36
protein (36) 36
binding sites (35) 35
insulin - metabolism (35) 35
peptidase (35) 35
degradation (34) 34
dipeptidyl-peptidase iv inhibitors - adverse effects (34) 34
dpp‐iv inhibitor (34) 34
drug therapy, combination (34) 34
in-vitro (34) 34
administration, oral (33) 33
crystal-structure (33) 33
dipeptidyl peptidase-4 inhibitor (33) 33
type 2 diabetes mellitus (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (738) 738
French (5) 5
Japanese (4) 4
Polish (4) 4
German (3) 3
Arabic (2) 2
Spanish (2) 2
Czech (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 761 - 765
We assessed the efficacy and safety of sitagliptin compared with α‐glucosidase inhibitor ( αGI ) in 120 of Japanese patients with type 2 diabetes mellitus (... 
type 2 diabetes | DPP‐IV | inhibitor | sulphonylureas | α‐glucosidase inhibitor | randomized trial | Type 2 diabetes | Randomized trial | α-glucosidase inhibitor | Sulphonylureas | DPP-IV inhibitor | VOGLIBOSE | MONOTHERAPY | HYPERGLYCEMIA | DOUBLE-BLIND TRIAL | alpha-glucosidase inhibitor | ENDOCRINOLOGY & METABOLISM | MELLITUS | Glycated Hemoglobin A - analysis | Triazoles - adverse effects | Glycoside Hydrolase Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Pyrazines - therapeutic use | Hypoglycemia - prevention & control | 1-Deoxynojirimycin - therapeutic use | Drug Therapy, Combination - adverse effects | Inositol - therapeutic use | Inositol - adverse effects | 1-Deoxynojirimycin - analogs & derivatives | Female | 1-Deoxynojirimycin - adverse effects | Sitagliptin Phosphate | Hypoglycemia - chemically induced | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Japan | Sulfonylurea Compounds - therapeutic use | Inositol - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Gastrointestinal Agents - therapeutic use | Pyrazines - adverse effects | Aged | Gastrointestinal Agents - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | alpha-Glucosidases - metabolism | alpha-Glucosidases - chemistry | Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2005, Volume 48, Issue 1, pp. 141 - 151
Journal Article
International Journal of Food Science & Technology, ISSN 0950-5423, 05/2018, Volume 53, Issue 5, pp. 1166 - 1175
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2018, Volume 20, Issue 5, pp. 1111 - 1120
Aim: To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are... 
clinical trial | phase | study | type 2 diabetes | DPP‐IV | inhibitor | SGLT2 | III | glycaemic control | SGLT2 inhibitor | phase III study | DPP-IV inhibitor | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | MONOTHERAPY | EFFICACY | SAFETY | COMBINATION | BLOOD-PRESSURE | GLUCOSE COTRANSPORTER 2 | THERAPY | ENDOCRINOLOGY & METABOLISM | EMPAGLIFLOZIN | Glycated Hemoglobin A - analysis | Overweight - complications | Metformin - therapeutic use | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Drug Therapy, Combination - adverse effects | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - administration & dosage | Female | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Drug Resistance | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Double-Blind Method | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Diabetes Mellitus, Type 2 - blood | Sitagliptin Phosphate - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Sitagliptin Phosphate - adverse effects | Hypertension | Type 2 diabetes | Medical research | Care and treatment | Body weight | Clinical trials | Glycosylated hemoglobin | Mycoses | Complications and side effects | Analysis | Medicine, Experimental | Urinary tract infections | Hypoglycemic agents | Diabetes therapy | Diabetes mellitus | Hemoglobin | Blood pressure | Urinary tract | Diabetes | Metformin | Hypoglycemia | Diabetes mellitus (non-insulin dependent) | Index Medicus | DPP‐IV inhibitor | Original
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 10/2012, Volume 20, Issue 19, pp. 5705 - 5719
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2013, Volume 15, Issue 7, pp. 668 - 673
Aim As there have been concerns that some classes or agents for the treatment of type 2 diabetes may increase CV risk, we evaluated the cardiovascular profile... 
cardiovascular disease | type 2 diabetes | DPP‐IV | inhibitor | Type 2 diabetes | Cardiovascular disease | DPP-IV inhibitor | METFORMIN | MONOTHERAPY | GLP-1 | EFFICACY | INADEQUATE GLYCEMIC CONTROL | PIOGLITAZONE | GLUCOSE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | THERAPIES | OUTCOMES | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Diabetic Cardiomyopathies - physiopathology | Incidence | Cardiovascular Diseases - complications | Diabetic Angiopathies - physiopathology | Cardiovascular Diseases - epidemiology | Female | Diabetes Mellitus, Type 2 - complications | Severity of Illness Index | Diabetic Angiopathies - chemically induced | Cardiovascular Diseases - physiopathology | Double-Blind Method | Proportional Hazards Models | Uracil - therapeutic use | Uracil - adverse effects | Piperidines - therapeutic use | Diabetic Cardiomyopathies - epidemiology | Piperidines - adverse effects | Diabetic Angiopathies - epidemiology | Aged | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Diabetic Cardiomyopathies - chemically induced | Cohort Studies | Uracil - analogs & derivatives | Hypoglycemic agents | Safety and security measures | Analysis | Heart attack | Confidence intervals | Medical research | Heart attacks | Diabetes | Index Medicus
Journal Article
Peptides, ISSN 0196-9781, 10/2018, Volume 108, pp. 34 - 45
Protease inhibition has become a new possible approach in the inflammatory bowel disease (IBD) therapy. A serine exopeptidase, dipeptidyl peptidase IV (DPP IV)... 
Inflammation | IBD | Colitis | DPP IV inhibitor | THERAPEUTIC STRATEGY | BIOCHEMISTRY & MOLECULAR BIOLOGY | RECEPTOR | COLON | MURINE | ISOTHERMAL TITRATION CALORIMETRY | INFLAMMATORY-BOWEL-DISEASE | GLUCAGON-LIKE PEPTIDE-2 | GROWTH | ENDOCRINOLOGY & METABOLISM | PHARMACOLOGY & PHARMACY | MICE | GLP-2 | Models | Fluocinolone acetonide | Proteases | Analysis | Ulcerative colitis | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2007, Volume 9, Issue 5, pp. 733 - 745
Journal Article
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 11/2014, Volume 16, Issue 11, pp. 1078 - 1086
  Aims To investigate individual patient data from a comprehensive trials programme to evaluate the safety and efficacy of the dipeptidyl peptidase-4 (DPP-4)... 
Diabetes mellitus | DPP-IV inhibitor | Drug therapy | Medical research | Diabetes
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 03/2007, Volume 9, Issue 2, pp. 194 - 205
Journal Article